March 15th, 2013
FDA Studying Whether Certain Diabetes Drugs Pose Pre-Cancer Risk
The FDA is investigating whether diabetes drugs in the class known as incretin mimetics pose an increased risk for pancreatic duct metaplasia.
The agency is looking at unpublished data on pancreatic toxicity in a small number of tissue samples taken from patients with diabetes who died. It will examine the researchers’ methodology and the samples firsthand before concluding whether there is a risk to patients.
Incretin mimetics include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). The drugs’ labels already carry warnings about the risk for pancreatitis.
Healthcare providers may continue prescribing the drugs according to the labels and should report adverse events to the FDA.